Lamivudine resistance in hepatitis B: Mechanisms and clinical implications

Drug Resistance Updates

Volumn 4, Issue 2, 2001, Pages 118-128

  Fischer, Karl P ^a,c   Gutfreund, Klaus S ^b   Tyrrell, D Lorne ^a,b,c  

^a Departments of Medical Microbiology

^b Medicine

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CLEVUDINE; ELVUCITABINE; ENTECAVIR; FAMCICLOVIR; HUMAN IMMUNOGLOBULIN; LAMIVUDINE; LOBUCAVIR; PENCICLOVIR; PURINE DERIVATIVE; TENOFOVIR; VIRUS ENZYME;

DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS RESISTANCE;

EID: 0034930498     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0190     Document Type: Article

References (133)

1. Hepatitis B: Global importance and need for control
2. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan
3. Hepatitis B virus. The major etiology of hepatocellular carcinoma
4. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
5. Global status of hepatitis B immunization
6. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
7. Phase II trial of lamivudine for chronic hepatitis B
8. Lamivudine as initial treatment for chronic hepatitis B in the United States
9. A preliminary trial of lamivudine for chronic hepatitis B infection
10. A one-year trial of lamivudine for chronic hepatitis B
11. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
12. Experience with lamivudine against hepatitis B virus
13. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
14. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
15. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
16. Long-term remission of chronic hepatitis B after alphainterferon therapy
17. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
18. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B
19. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
20. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors
21. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon
22. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
23. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
24. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
25. Hepatitis B reactivation after lamivudine
26. Three year lamivudine therapy in chronic HBV
27. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
28. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
29. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials
30. Seroconversion after lamivudine is not durable in chronic hepatitis B
31. Hepatitis B virus reactivation after lamivudine discontinuation
32. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B
33. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion
34. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
35. A placebo controlled study of lamivudine and interferon alpha 2-b in patients with chronic hepatitis B who previously failed interferon therapy
36. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
37. Liver transplantation in European patients with the hepatitis B surface antigen
38. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis
39. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation
40. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
41. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
42. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT)
43. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
44. Lamivudine for hepatitis B in liver transplantation: A single-center experience
45. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
46. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
47. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
48. Lamivudine treatment for acute hepatitis B after liver transplantation
49. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
50. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine treated hepatitis B patients
51. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
52. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
53. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine
54. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
55. The seperated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro
56. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
57. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro
58. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV)
59. Pure nucleoside enantiomers of beta-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro
60. The biochemical basis for the differential ant-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine
61. Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy 3′-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera
62. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
63. Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
64. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
65. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
66. High-level resistance to (-) enantiomeric 2′-deoxy-3′thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
67. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine
68. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
69. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] in vitro
70. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
71. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
72. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
73. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance
74. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
75. Emergence and characterisation of lamivudine resistant hepatitis B virus variant
76. Clinical relevance of mutations in the precore genome of the hepatitis B virus
77. The sequential occurrence of viral mutations in a liver transplant recipient reinfected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
78. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
79. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B
80. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
81. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
82. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A Study by in vitro full-length viral DNA transfection
83. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
84. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hinderance with beta-branched amino acids
85. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses
86. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans
87. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks
88. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
89. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
90. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
91. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
92. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
93. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
94. In vitro analysis of a novel HBV mutation associated with clinical resistance to lamivudine distinct from the YMDD mutation
95. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
96. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation
97. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
98. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
99. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
100. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
101. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
102. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation
103. Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: A preliminary report
104. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
105. Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: Application to emergence of lamivudine-resistant hepatitis B virus
106. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro
107. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells
108. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients
109. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients
110. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy
111. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: An analysis of the CAESAR study
112. Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: Combined effect for both infections, an obtainable goal?
113. Two sensitive PCR-based methods for detection of hepatitis B virus variants with reduced susceptibility to lamivudine
114. Use of real- time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus
115. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants
116. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy
117. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays
118. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations
119. Phosphonylmethoxyalkyl derivatives of purine as inhibitors of human hepatitis B virus DNA synthesis
120. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
121. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir
122. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
123. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
124. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
125. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
126. The hepatitis B Virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
127. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
128. The implications of drug resistance for strategies of combination antiviral chemotherapy
129. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV-infected patients
130. Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV
131. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro
132. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: A viral dynamics study
133. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance